{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?sponsor=Mundipharma+Research+Limited",
    "query": {
      "sponsor": "Mundipharma Research Limited"
    },
    "page_size": 10
  },
  "pagination": {
    "page": 1,
    "page_size": 10,
    "total_count": 4,
    "total_pages": 1,
    "next_page_url": null,
    "previous_page_url": null
  },
  "source": "remote",
  "last_synced_at": "2026-09-30T04:53:47.347Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT02576496",
      "title": "Study of Tinostamustine, First-in-Class Alkylating HDACi Fusion Molecule, in Relapsed/Refractory Hematologic Malignancies",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Hematological Malignancies",
        "Multiple Myeloma",
        "Hodgkin's Lymphoma",
        "Cutaneous T Cell Lymphoma"
      ],
      "interventions": [
        {
          "name": "Tinostamustine",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Mundipharma Research Limited",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 106,
      "start_date": "2016-04-14",
      "completion_date": "2023-11-21",
      "has_results": false,
      "last_update_posted_date": "2024-07-25",
      "last_synced_at": "2026-09-30T04:53:47.347Z",
      "location_count": 4,
      "location_summary": "Phoenix, Arizona • Jacksonville, Florida • New York, New York + 1 more",
      "locations": [
        {
          "city": "Phoenix",
          "state": "Arizona"
        },
        {
          "city": "Jacksonville",
          "state": "Florida"
        },
        {
          "city": "New York",
          "state": "New York"
        },
        {
          "city": "Cleveland",
          "state": "Ohio"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02576496"
    },
    {
      "nct_id": "NCT02326454",
      "title": "A Placebo Controlled Study of MR901 (Talaporfin Sodium Sodium + a Drug-activating Device) for the Relief of Lower Urinary Tract Symptoms Due to Benign Prostatic Hyperplasia",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Benign Prostatic Hyperplasia"
      ],
      "interventions": [
        {
          "name": "talaporfin sodium",
          "type": "DRUG"
        },
        {
          "name": "Saline",
          "type": "DRUG"
        },
        {
          "name": "Drug Activator 100 J/cm",
          "type": "DEVICE"
        },
        {
          "name": "Drug Activator 200 J/cm",
          "type": "DEVICE"
        }
      ],
      "intervention_types": [
        "DRUG",
        "DEVICE"
      ],
      "sponsor": "Light Sciences Oncology",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "40 Years",
        "maximum_age": null,
        "sex": "MALE",
        "summary": "40 Years and older · Male only"
      },
      "enrollment_count": 225,
      "start_date": "2014-11",
      "completion_date": "2017-03-29",
      "has_results": false,
      "last_update_posted_date": "2018-08-08",
      "last_synced_at": "2026-09-30T04:53:47.347Z",
      "location_count": 41,
      "location_summary": "Anniston, Alabama • Huntsville, Alabama • Anchorage, Alaska + 37 more",
      "locations": [
        {
          "city": "Anniston",
          "state": "Alabama"
        },
        {
          "city": "Huntsville",
          "state": "Alabama"
        },
        {
          "city": "Anchorage",
          "state": "Alaska"
        },
        {
          "city": "Laguna Hills",
          "state": "California"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02326454"
    },
    {
      "nct_id": "NCT04368559",
      "title": "Study of Rezafungin Compared to Standard Antimicrobial Regimen for Prevention of Invasive Fungal Diseases in Adults Undergoing Allogeneic Blood and Marrow Transplantation",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Candidemia",
        "Mycoses",
        "Fungal Infection",
        "Fungemia",
        "Invasive Candidiasis",
        "Pneumocystis",
        "Mold Infection",
        "Invasive Fungal Disease",
        "Prophylaxis of Invasive Fungal Infections",
        "Aspergillus"
      ],
      "interventions": [
        {
          "name": "Rezafungin for Injection",
          "type": "DRUG"
        },
        {
          "name": "Posaconazole",
          "type": "DRUG"
        },
        {
          "name": "Fluconazole",
          "type": "DRUG"
        },
        {
          "name": "Trimethoprim-sulfamethoxazole (TMP/SMX)",
          "type": "DRUG"
        },
        {
          "name": "Intravenous Placebo",
          "type": "DRUG"
        },
        {
          "name": "Oral Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Mundipharma Research Limited",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 602,
      "start_date": "2020-05-11",
      "completion_date": "2026-01-29",
      "has_results": false,
      "last_update_posted_date": "2026-04-13",
      "last_synced_at": "2026-09-30T04:53:47.347Z",
      "location_count": 18,
      "location_summary": "Birmingham, Alabama • Los Angeles, California • Stanford, California + 13 more",
      "locations": [
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Stanford",
          "state": "California"
        },
        {
          "city": "Augusta",
          "state": "Georgia"
        },
        {
          "city": "Chicago",
          "state": "Illinois"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04368559"
    },
    {
      "nct_id": "NCT03345485",
      "title": "Study of the Safety, Pharmacokinetics and Efficacy of Tinostamustine in Patients With Advanced Solid Tumors.",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1",
        "PHASE2"
      ],
      "conditions": [
        "Small Cell Lung Cancer",
        "Soft Tissue Sarcoma",
        "Triple-negative Breast Cancer",
        "Ovarian Cancer",
        "Endometrial Cancer"
      ],
      "interventions": [
        {
          "name": "Tinostamustine 60mg/m2 over 30min",
          "type": "DRUG"
        },
        {
          "name": "Tinostamustine 80mg/m2 over 30min",
          "type": "DRUG"
        },
        {
          "name": "Tinostamustine 100mg/m2 over 30min",
          "type": "DRUG"
        },
        {
          "name": "Tinostamustine 60mg/m2 over 60min",
          "type": "DRUG"
        },
        {
          "name": "Tinostamustine 80mg/m2 over 60min",
          "type": "DRUG"
        },
        {
          "name": "Tinostamustine 100mg/m2 over 60min",
          "type": "DRUG"
        },
        {
          "name": "Tinostamustine 80mg/m2 over 80min",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Mundipharma Research Limited",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 71,
      "start_date": "2017-11-08",
      "completion_date": "2023-03-29",
      "has_results": true,
      "last_update_posted_date": "2024-10-21",
      "last_synced_at": "2026-09-30T04:53:47.347Z",
      "location_count": 5,
      "location_summary": "Los Angeles, California • Palo Alto, California • Ann Arbor, Michigan + 2 more",
      "locations": [
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Palo Alto",
          "state": "California"
        },
        {
          "city": "Ann Arbor",
          "state": "Michigan"
        },
        {
          "city": "New York",
          "state": "New York"
        },
        {
          "city": "Dallas",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03345485"
    }
  ]
}